The impact of hepatitis B virus infected patients or donors on the outcome of hematopoietic stem cell transplantation

S. Feng, M. Han, L. Zhang, C. Li, L. Qiu, H. Li, Zack Z. Wang, R. Jiang, W. Yan, Z. Han

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To investigate the impact of recipients and/or donors infected with hepatitis B on the outcome of hematopoietic stem cells transplantation (HSCT). METHODS: We analyzed retrospectively the transplantation outcome in 26 of 164 hematological diseases patients who and whose donors were infected with hepatitis prior to transplantation. RESULTS: (1) Three of the 26 patients developed VOD after HSCT, the incidence (11.5%) is significant higher than that in patients and donors who did not infected with HBV (P <0.05). (2) Two of 5 patients transfused hematopoietic stem cells from HBsAg + donors developed hepatitis B. (3) Four patients with allogeneic stem cell transplantation developed hepatic failure (HF) which occurred during cyclosporin (CsA) being tapered off or withdrawal. The incidence of HF in patients and/or donors infected with HBV (15.4%) is obviously higher than that in patients and donors who did not (0.08%, P <0.01). (4) In 4 patients with HbeAg +, 2 patients died of HF after allogeneic HSCT, the other 2 patients survived after autologous HSCT. CONCLUSION: Donors and recipients infected with hepatitis B are not contraindication of HSCT, but patients with allogeneic HSCT are in danger to develop LF during CsA being tapered off or withdrawal.

Original languageEnglish (US)
Pages (from-to)414-416
Number of pages3
JournalZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Volume21
Issue number8
StatePublished - 2000
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Hepatitis B virus
Tissue Donors
Liver Failure
Hepatitis B
Transplantation
Hematologic Diseases
Incidence
Stem Cell Transplantation
Hepatitis B Surface Antigens
Hematopoietic Stem Cells
Cyclosporine
Hepatitis

Cite this

The impact of hepatitis B virus infected patients or donors on the outcome of hematopoietic stem cell transplantation. / Feng, S.; Han, M.; Zhang, L.; Li, C.; Qiu, L.; Li, H.; Wang, Zack Z.; Jiang, R.; Yan, W.; Han, Z.

In: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, Vol. 21, No. 8, 2000, p. 414-416.

Research output: Contribution to journalArticle

Feng, S. ; Han, M. ; Zhang, L. ; Li, C. ; Qiu, L. ; Li, H. ; Wang, Zack Z. ; Jiang, R. ; Yan, W. ; Han, Z. / The impact of hepatitis B virus infected patients or donors on the outcome of hematopoietic stem cell transplantation. In: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2000 ; Vol. 21, No. 8. pp. 414-416.
@article{3321b2d300b64052a02044d23c65eb80,
title = "The impact of hepatitis B virus infected patients or donors on the outcome of hematopoietic stem cell transplantation",
abstract = "OBJECTIVE: To investigate the impact of recipients and/or donors infected with hepatitis B on the outcome of hematopoietic stem cells transplantation (HSCT). METHODS: We analyzed retrospectively the transplantation outcome in 26 of 164 hematological diseases patients who and whose donors were infected with hepatitis prior to transplantation. RESULTS: (1) Three of the 26 patients developed VOD after HSCT, the incidence (11.5{\%}) is significant higher than that in patients and donors who did not infected with HBV (P <0.05). (2) Two of 5 patients transfused hematopoietic stem cells from HBsAg + donors developed hepatitis B. (3) Four patients with allogeneic stem cell transplantation developed hepatic failure (HF) which occurred during cyclosporin (CsA) being tapered off or withdrawal. The incidence of HF in patients and/or donors infected with HBV (15.4{\%}) is obviously higher than that in patients and donors who did not (0.08{\%}, P <0.01). (4) In 4 patients with HbeAg +, 2 patients died of HF after allogeneic HSCT, the other 2 patients survived after autologous HSCT. CONCLUSION: Donors and recipients infected with hepatitis B are not contraindication of HSCT, but patients with allogeneic HSCT are in danger to develop LF during CsA being tapered off or withdrawal.",
author = "S. Feng and M. Han and L. Zhang and C. Li and L. Qiu and H. Li and Wang, {Zack Z.} and R. Jiang and W. Yan and Z. Han",
year = "2000",
language = "English (US)",
volume = "21",
pages = "414--416",
journal = "Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
issn = "0253-2727",
publisher = "Zhongguo Yixue Kexueyuan",
number = "8",

}

TY - JOUR

T1 - The impact of hepatitis B virus infected patients or donors on the outcome of hematopoietic stem cell transplantation

AU - Feng, S.

AU - Han, M.

AU - Zhang, L.

AU - Li, C.

AU - Qiu, L.

AU - Li, H.

AU - Wang, Zack Z.

AU - Jiang, R.

AU - Yan, W.

AU - Han, Z.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: To investigate the impact of recipients and/or donors infected with hepatitis B on the outcome of hematopoietic stem cells transplantation (HSCT). METHODS: We analyzed retrospectively the transplantation outcome in 26 of 164 hematological diseases patients who and whose donors were infected with hepatitis prior to transplantation. RESULTS: (1) Three of the 26 patients developed VOD after HSCT, the incidence (11.5%) is significant higher than that in patients and donors who did not infected with HBV (P <0.05). (2) Two of 5 patients transfused hematopoietic stem cells from HBsAg + donors developed hepatitis B. (3) Four patients with allogeneic stem cell transplantation developed hepatic failure (HF) which occurred during cyclosporin (CsA) being tapered off or withdrawal. The incidence of HF in patients and/or donors infected with HBV (15.4%) is obviously higher than that in patients and donors who did not (0.08%, P <0.01). (4) In 4 patients with HbeAg +, 2 patients died of HF after allogeneic HSCT, the other 2 patients survived after autologous HSCT. CONCLUSION: Donors and recipients infected with hepatitis B are not contraindication of HSCT, but patients with allogeneic HSCT are in danger to develop LF during CsA being tapered off or withdrawal.

AB - OBJECTIVE: To investigate the impact of recipients and/or donors infected with hepatitis B on the outcome of hematopoietic stem cells transplantation (HSCT). METHODS: We analyzed retrospectively the transplantation outcome in 26 of 164 hematological diseases patients who and whose donors were infected with hepatitis prior to transplantation. RESULTS: (1) Three of the 26 patients developed VOD after HSCT, the incidence (11.5%) is significant higher than that in patients and donors who did not infected with HBV (P <0.05). (2) Two of 5 patients transfused hematopoietic stem cells from HBsAg + donors developed hepatitis B. (3) Four patients with allogeneic stem cell transplantation developed hepatic failure (HF) which occurred during cyclosporin (CsA) being tapered off or withdrawal. The incidence of HF in patients and/or donors infected with HBV (15.4%) is obviously higher than that in patients and donors who did not (0.08%, P <0.01). (4) In 4 patients with HbeAg +, 2 patients died of HF after allogeneic HSCT, the other 2 patients survived after autologous HSCT. CONCLUSION: Donors and recipients infected with hepatitis B are not contraindication of HSCT, but patients with allogeneic HSCT are in danger to develop LF during CsA being tapered off or withdrawal.

UR - http://www.scopus.com/inward/record.url?scp=1842836374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842836374&partnerID=8YFLogxK

M3 - Article

C2 - 11877014

AN - SCOPUS:1842836374

VL - 21

SP - 414

EP - 416

JO - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

SN - 0253-2727

IS - 8

ER -